These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
555 related articles for article (PubMed ID: 10810387)
1. c-erbB-2 oncoprotein is overexpressed in poorly vascularised squamous cell carcinomas of the head and neck, but is not associated with response to cytotoxic therapy or survival. Giatromanolaki A; Koukourakis MI; Sivridis E; Fountzilas G Anticancer Res; 2000; 20(2A):997-1004. PubMed ID: 10810387 [TBL] [Abstract][Full Text] [Related]
2. p53 and bcl-2 expression in locally advanced squamous cell head-neck cancer treated with platinum based chemotherapy and radiotherapy. Giatromanolaki A; Koukourakis M; Zaramboukas T; Skordalaki A; Arapantoni P; Georgoulias V; Fountzilas G Anticancer Res; 1998; 18(6B):4685-92. PubMed ID: 9891541 [TBL] [Abstract][Full Text] [Related]
3. Angiogenesis, thymidine phosphorylase, and resistance of squamous cell head and neck cancer to cytotoxic and radiation therapy. Koukourakis MI; Giatromanolaki A; Fountzilas G; Sivridis E; Gatter KC; Harris AL Clin Cancer Res; 2000 Feb; 6(2):381-9. PubMed ID: 10690514 [TBL] [Abstract][Full Text] [Related]
4. Predictive and prognostic markers in a series of patients with head and neck squamous cell invasive carcinoma treated with concurrent chemoradiation therapy. Gasparini G; Bevilacqua P; Bonoldi E; Testolin A; Galassi A; Verderio P; Boracchi P; Guglielmi RB; Pezzella F Clin Cancer Res; 1995 Nov; 1(11):1375-83. PubMed ID: 9815934 [TBL] [Abstract][Full Text] [Related]
5. Tumour stage, node stage, p53 gene status, and bcl-2 protein expression as predictors of tumour response to platin-fluorouracil chemotherapy in patients with squamous-cell carcinoma of the head and neck. Fouret P; Temam S; Charlotte F; Lacau-St-Guily J Br J Cancer; 2002 Dec; 87(12):1390-5. PubMed ID: 12454767 [TBL] [Abstract][Full Text] [Related]
6. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy. Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582 [TBL] [Abstract][Full Text] [Related]
7. p53 but not bcl-2 immunostaining is predictive of poor clinical complete response to primary chemotherapy in breast cancer patients. Bottini A; Berruti A; Bersiga A; Brizzi MP; Brunelli A; Gorzegno G; DiMarco B; Aguggini S; Bolsi G; Cirillo F; Filippini L; Betri E; Bertoli G; Alquati P; Dogliotti L Clin Cancer Res; 2000 Jul; 6(7):2751-8. PubMed ID: 10914720 [TBL] [Abstract][Full Text] [Related]
8. Necessity for adjuvant neck dissection in setting of concurrent chemoradiation for advanced head-and-neck cancer. Brizel DM; Prosnitz RG; Hunter S; Fisher SR; Clough RL; Downey MA; Scher RL Int J Radiat Oncol Biol Phys; 2004 Apr; 58(5):1418-23. PubMed ID: 15050318 [TBL] [Abstract][Full Text] [Related]
9. Prognostic value of the epidermal growth factor receptor (EGRF) and p53 in advanced head and neck squamous cell carcinoma patients treated with induction chemotherapy. Hitt R; Ciruelos E; Amador ML; Benito A; Sanchez JJ; Ballestin C; Cortes-Funes H Eur J Cancer; 2005 Feb; 41(3):453-60. PubMed ID: 15691646 [TBL] [Abstract][Full Text] [Related]
10. Topoisomerase II alpha expression in squamous cell carcinomas of the head and neck. Stathopoulos GP; Kapranos N; Manolopoulos L; Papadimitriou C; Adamopoulos G Anticancer Res; 2000; 20(1A):177-82. PubMed ID: 10769652 [TBL] [Abstract][Full Text] [Related]
11. Analysis of prognostic variables among patients with locally advanced head and neck cancer treated with late chemo-intensification protocol: impact of nodal density and total tumor volume. Chufal KS; Rastogi M; Srivastava M; Pant MC; Bhatt ML; Srivastava K Jpn J Clin Oncol; 2006 Sep; 36(9):537-46. PubMed ID: 16905755 [TBL] [Abstract][Full Text] [Related]
12. Bilharzial related, organ confined, muscle invasive bladder cancer: prognostic value of apoptosis markers, proliferation markers, p53, E-cadherin, epidermal growth factor receptor and c-erbB-2. Haitel A; Posch B; El-Baz M; Mokhtar AA; Susani M; Ghoneim MA; Marberger M J Urol; 2001 May; 165(5):1481-7. PubMed ID: 11342901 [TBL] [Abstract][Full Text] [Related]
13. Predictors of response to chemo-radiotherapy and radiotherapy for esophageal squamous cell carcinoma. Miyazaki T; Kato H; Faried A; Sohda M; Nakajima M; Fukai Y; Masuda N; Manda R; Fukuchi M; Ojima H; Tsukada K; Kuwano H Anticancer Res; 2005; 25(4):2749-55. PubMed ID: 16080521 [TBL] [Abstract][Full Text] [Related]
14. Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer. Geisler S; Lønning PE; Aas T; Johnsen H; Fluge O; Haugen DF; Lillehaug JR; Akslen LA; Børresen-Dale AL Cancer Res; 2001 Mar; 61(6):2505-12. PubMed ID: 11289122 [TBL] [Abstract][Full Text] [Related]
15. Evaluation of P-glycoprotein, HER-2/ErbB-2, p53, and Bcl-2 in primary tumor and metachronous lung metastases in patients with high-grade osteosarcoma. Ferrari S; Bertoni F; Zanella L; Setola E; Bacchini P; Alberghini M; Versari M; Bacci G Cancer; 2004 May; 100(9):1936-42. PubMed ID: 15112275 [TBL] [Abstract][Full Text] [Related]
16. Prognostic value of p53, glutathione S-transferase pi, and thymidylate synthase for neoadjuvant cisplatin-based chemotherapy in head and neck cancer. Shiga H; Heath EI; Rasmussen AA; Trock B; Johnston PG; Forastiere AA; Langmacher M; Baylor A; Lee M; Cullen KJ Clin Cancer Res; 1999 Dec; 5(12):4097-104. PubMed ID: 10632346 [TBL] [Abstract][Full Text] [Related]
17. Vascular endothelial growth factor, p53, Rb, Bcl-2 expression and response to chemotherapy in advanced non-small cell lung cancer. Ludovini V; Gregorc V; Pistola L; Mihaylova Z; Floriani I; Darwish S; Stracci F; Tofanetti FR; Ferraldeschi M; Di Carlo L; Ragusa M; Daddi G; Tonato M Lung Cancer; 2004 Oct; 46(1):77-85. PubMed ID: 15364135 [TBL] [Abstract][Full Text] [Related]
18. MASPIN's prognostic role in patients with advanced head and neck carcinoma treated with primary chemotherapy (carboplatin plus vinorelbine) and radiotherapy: preliminary evidence. Marioni G; Koussis H; Gaio E; Giacomelli L; Bertolin A; D'Alessandro E; Scola A; Ottaviano G; de Filippis C; Jirillo A; Staffieri A; Blandamura S Acta Otolaryngol; 2009 Jul; 129(7):786-92. PubMed ID: 18819022 [TBL] [Abstract][Full Text] [Related]
19. Neck dissection in the combined-modality therapy of patients with locoregionally advanced head and neck cancer. Argiris A; Stenson KM; Brockstein BE; Mittal BB; Pelzer H; Kies MS; Jayaram P; Portugal L; Wenig BL; Rosen FR; Haraf DJ; Vokes EE Head Neck; 2004 May; 26(5):447-55. PubMed ID: 15122662 [TBL] [Abstract][Full Text] [Related]
20. c-erbB-2 oncogene related to p53 expression, cell proliferation and prognosis in breast cancer. Lipponen HJ; Aaltomaa S; Syrjänen S; Syrjänen K Anticancer Res; 1993; 13(4):1147-52. PubMed ID: 8102517 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]